Trial Profile
A Phase II Randomized, Double-Blind, Placebo-Controlled, Cross-Over Study Investigating the Safety and Efficacy of Omnitram in Diabetic Neuropathy
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 21 Sep 2020
Price :
$35
*
At a glance
- Drugs Desmetramadol (Primary)
- Indications Neuropathic pain; Pain
- Focus Therapeutic Use
- Sponsors Syntrix Biosystems
- 16 Sep 2020 Status changed from active, no longer recruiting to completed.
- 14 May 2020 Planned primary completion date changed from 1 Jun 2020 to 1 Aug 2020.
- 14 May 2020 Status changed from recruiting to active, no longer recruiting.